Springworks Company Profile
What is the competitive landscape for SPRINGWORKS
SPRINGWORKS has three approved drugs.
There are fifty-two US patents protecting SPRINGWORKS drugs.
Summary for Springworks
| US Patents: | 52 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 3 |
Drugs and US Patents for Springworks
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-001 | Nov 27, 2023 | DISCN | Yes | No | 11,925,619 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Springworks | GOMEKLI | mirdametinib | TABLET, FOR SUSPENSION;ORAL | 219379-001 | Feb 11, 2025 | RX | Yes | Yes | 11,084,780 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Springworks | GOMEKLI | mirdametinib | TABLET, FOR SUSPENSION;ORAL | 219379-001 | Feb 11, 2025 | RX | Yes | Yes | 12,661,330 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-003 | Apr 4, 2024 | RX | Yes | Yes | 11,844,780 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-001 | Nov 27, 2023 | DISCN | Yes | No | 11,925,620 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-001 | Nov 27, 2023 | DISCN | Yes | No | 12,011,434 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-002 | Apr 4, 2024 | RX | Yes | No | 12,247,012 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Springworks
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-002 | Apr 4, 2024 | 7,951,958 | ⤷ Start Trial |
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-003 | Apr 4, 2024 | 7,342,118 | ⤷ Start Trial |
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-001 | Nov 27, 2023 | 7,342,118 | ⤷ Start Trial |
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-003 | Apr 4, 2024 | 7,951,958 | ⤷ Start Trial |
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-002 | Apr 4, 2024 | 7,342,118 | ⤷ Start Trial |
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-001 | Nov 27, 2023 | 7,951,958 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Springworks Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Colombia | 2024013937 | ⤷ Start Trial |
| Argentina | 126961 | ⤷ Start Trial |
| Mexico | 2024005453 | ⤷ Start Trial |
| Chile | 2024002760 | ⤷ Start Trial |
| Israel | 311128 | ⤷ Start Trial |
| European Patent Office | 4493539 | ⤷ Start Trial |
| European Patent Office | 4680218 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Springworks Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 4010322 | CA 2026 00017 | Denmark | ⤷ Start Trial | PRODUCT NAME: KRYSTALLINSK FORM AF ET HYDROBROMID SALT AF NIROGACESTAT, SAERLIGT EN KRYSTALLINSK FORM AF DIHYDROBROMID SALTET AF NIROGACESTAT; REG. NO/DATE: EU/1/25/1932 20250818 |
| 4010322 | CR 2026 00017 | Denmark | ⤷ Start Trial | PRODUCT NAME: KRYSTALLINSK FORM AF ET HYDROBROMID SALT AF NIROGACESTAT, SAERLIGT EN KRYSTALLINSK FORM AF DIHYDROBROMID SALTET AF NIROGACESTAT; REG. NO/DATE: EU/1/25/1932 20250818 |
| 4010322 | 202640011 | Slovenia | ⤷ Start Trial | PRODUCT NAME: CRYSTALLINE FORM A OF A HYDROBROMIDE SALT OF NIROGACESTAT, PREFERABLY A CRYSTALLINE FORM A OF THE DIHYDROBROMIDE SALT OF NIROGACESTAT; NATIONAL AUTHORISATION NUMBER: EU/1/25/1932/001-004; DATE OF NATIONAL AUTHORISATION: 20250814; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 4010322 | 2026C/718 | Belgium | ⤷ Start Trial | PRODUCT NAME: KRISTALLIJNE VORM VAN EEN HYDROBROMIDEZOUT VAN NIROGACESTAT, BIJ VOORKEUR EEN KRISTALLIJNE VORM VAN HET DIHYDROBROMIDEZOUT VAN NIROGACESTAT; AUTHORISATION NUMBER AND DATE: EU/1/25/1932 20250818 |
| 4010322 | LUC50046 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: FORME CRISTALLINE D'UN SEL D'HYDROBROMURE DE NIROGACESTAT, DE PREFERENCE UNE FORME CRISTALLINE DU SEL DE DIHYDROBROMURE DE NIROGACESTAT; AUTHORISATION NUMBER AND DATE: EU/1/25/1932 20250818 |
| 4010322 | C20260011 | Finland | ⤷ Start Trial | |
| 4010322 | PA2026516 | Lithuania | ⤷ Start Trial | PRODUCT NAME: OGSIVEO - NIROGACESTATAS; REGISTRATION NO/DATE: EU/1/25/1932 20250814 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
